MULTIPLE MYELOMA TREATMENT

1 . A method of treating multiple myeloma (MM) in an individual, the method comprising:

determining or having determined, from a biological sample obtained from the individual’s body, that a level of expression of one or more gene selected from a group consisting of: CCNB1 and CDC2 is indicative of overexpression; and

administering to the individual an effective amount of trichostatin A (TSA),

wherein the effective amount is between about 0.01 mg/kg/day and about 100 mg/kg/day and effective to decrease expression of the one or more gene.

2 . The method of claim 1 , wherein the effective amount is an amount sufficient to decrease expression of each of CCNB1 and CDC2.

3 . The method of claim 1 , wherein the effective amount is between about 0.1 mg/kg/day and about 10 mg/kg/day.

4 . The method of claim 1 , wherein the effective amount is between about 0.5 mg/kg/day and about 5 mg/kg/day.

5 . The improvement of claim 1 , wherein the TSA is administered orally.

6 . The improvement of claim 1 , wherein the TSA is administered intravenously.

7 . In a method of treating a patient diagnosed with multiple myeloma (MM) with trichostatin A (TSA), the improvement comprising:

selecting for treatment with between about 0.01 mg/kg/day and about 100 mg/kg/day a patient determined to overexpress at least one gene selected from a group consisting of: CCNB1 and CDC2.

8 . The improvement of claim 7 , wherein the effective amount is effective to decrease expression of both of CCNB1 and CDC2.

9 . The improvement of claim 7 , wherein the amount is between 0.1 mg/kg/day and 10 mg/kg/day.

10 . The improvement of claim 7 , wherein the amount is between 0.5 mg/kg/day and 5 mg/kg/day.

11 . The improvement of claim 7 , wherein the TSA is administered orally.

12 . The improvement of claim 7 , wherein the TSA is administered intravenously.